Thyroid Cancer Treatment: How Chemotherapy Use is Evolving
"Discover the latest trends in chemotherapy for thyroid cancer, including the role of multikinase inhibitors (MKIs) and factors influencing treatment decisions."
Thyroid cancer is on the rise, with over 64,000 people diagnosed each year. While most cases are highly treatable, some differentiated thyroid cancers (DTCs) and medullary thyroid cancers (MTCs) don't respond to standard therapies, leading to poorer outcomes. For these challenging cases, chemotherapy, including newer targeted drugs, may be considered.
Multikinase inhibitors (MKIs) emerged as a new treatment option, gaining FDA approval for MTC in 2011 and metastatic DTC in 2013. These drugs offer hope for slowing disease progression, but how have they impacted the overall use of chemotherapy in thyroid cancer treatment?
To understand the changing landscape, researchers analyzed data from the National Cancer Database (NCDB) between 2004 and 2013. The goal was to identify trends in chemotherapy use, including MKIs, among patients with DTC and MTC.
A Treatable but Varied Disease
Thyroid cancer includes multiple disease types with different biological behaviors and treatment needs. Its impact depends on factors such as cancer type, stage, overall health, and patient preferences. Treatment decisions therefore require individualized assessment rather than a single standard approach.
Treatment Depends on the Disease
Standard thyroid cancer care may include surgery, radiation therapy, radioactive iodine therapy, hormone therapy, targeted therapy, chemotherapy, or observation. These approaches are selected according to the cancer's type and stage and the patient's overall health. Because thyroid cancers differ substantially, a treatment that is appropriate for one patient may not be suitable for another.
From Uniform Care to Personalization
Thyroid cancer treatment has evolved from broadly uniform management toward more individualized care. Surgery remains important, but modern treatment planning also considers disease biology, stage, and patient-specific factors. This shift has expanded the role of observation, radioactive iodine, systemic therapies, and targeted treatment in selected settings.
Key Findings: Chemotherapy Use and Its Predictors
The study included nearly 200,000 patients, providing a comprehensive look at treatment patterns. The analysis revealed significant insights into chemotherapy use based on cancer type, stage, and other factors.
- MTC Treatment Shifts: Chemotherapy use in MTC increased from 3.1% (2004-2010) to 5.0% (2011-2013) following MKI approval. This increase was statistically significant, suggesting MKIs are influencing treatment decisions.
- Metastatic DTC Trends: Chemotherapy use in metastatic DTC was low, with 4.9% of patients receiving it in 2013. This rate was not significantly higher than in previous years, indicating limited MKI adoption in this group.
- Factors Influencing Chemotherapy: For MTC, metastatic disease, regional lymph node spread, and larger tumor size were associated with increased chemotherapy use. Patient demographics like gender and insurance type did not significantly impact the decision after adjusting for other factors.
- Facility Type: Facility type (community vs. teaching/research center) didn't significantly affect chemotherapy use, suggesting treatment decisions are consistent across different care settings.
Precision Medicine and New Therapies
Recent reviews describe a paradigm shift in thyroid cancer management from a uniform, surgery-dominated approach toward precision medicine. Current research includes tumor genetics, metabolism, and immunology, particularly in anaplastic thyroid cancer (ATC). Reviews and clinical programs are also examining novel therapies and clinical trials for advanced disease.
Why Chemotherapy Is Not Universal
Chemotherapy is one of several thyroid cancer treatment options, alongside surgery, radiation therapy, radioactive iodine therapy, hormone therapy, targeted therapy, and observation. The available choices reflect the fact that treatment must be matched to newly diagnosed or recurrent disease and to the cancer's type and stage. The American Society of Clinical Oncology's 2026 guideline was developed to provide evidence-based recommendations for systemic therapy across different thyroid cancers, underscoring the need for more selective treatment rather than assuming chemotherapy is appropriate for everyone.
Chemotherapy Versus Other Modalities
Available treatment comparisons indicate that chemotherapy is generally not the primary initial treatment for most thyroid cancers. The Advance Study source identifies surgery and radioactive iodine therapy as more common and effective initial approaches. The American Cancer Society emphasizes that treatment varies by cancer type and stage and that patients should weigh potential benefits against risks and side effects.
Implications and Future Directions
This study provides valuable insights into the evolving landscape of thyroid cancer treatment. The modest increase in chemotherapy use for MTC following MKI approval suggests these drugs are gradually being integrated into practice.
Evidence Is Moving Beyond Conventional Chemotherapy
Recent analyses evaluate modern therapeutic approaches for locally advanced, recurrent, and metastatic ATC, including targeted therapies. The 2024 Frontiers analysis synthesized efficacy and safety data from prospective studies of emerging chemotherapy-based treatments published from January 2010 through February 2024. A 2025 meta-analysis likewise assessed mutationally directed agents, chemotherapy, and radiotherapy, showing that treatment development is increasingly organized around both molecular targets and combined strategies.
Genomic Selection and Resistance Research
Future thyroid cancer research is expected to focus on emerging treatments in clinical trials and on mechanisms of resistance to targeted therapies. Another priority is identifying which patients are best suited to particular genomic-driven therapies. Market analyses also describe a treatment landscape spanning surgery, radioactive iodine therapy, thyroid hormone therapy, external radiation therapy, chemotherapy, and targeted therapy, with research and development and rising global incidence cited as growth drivers.
Resistance, Toxicity, and Access
Advanced thyroid cancer care remains challenged by drug resistance and treatment toxicity. A review of radioiodine-refractory thyroid cancer notes that systemic therapies can cause significant side effects that affect quality of life and that further research is needed on timing, sequencing, and personalized care. Sources also identify universal access to molecular testing and targeted therapies as an unresolved need, while ATC may require coordinated surgery, radiation, systemic therapy, and airway management.
Treatment in Everyday Practice
Real-world evidence on advanced thyroid cancer treated with lenvatinib remains limited, but one study reports valuable information about treatment patterns and outcomes. A 2025 study examined first-line lenvatinib in a genomically characterized cohort and sought clinicopathological and molecular correlates of response. A Cleveland Clinic case report describes a 46-year-old woman with metastatic papillary thyroid cancer who received standard lenvatinib treatment beginning in early 2019, illustrating how systemic therapy is applied in individual patient care.
However, the low uptake of chemotherapy for metastatic DTC warrants further investigation. Factors such as treatment costs, limited effectiveness, and physician preferences may be contributing to this trend.
Future research should focus on identifying predictive biomarkers to guide treatment decisions and optimize the use of MKIs and other chemotherapeutic agents in thyroid cancer. Continuous monitoring of treatment patterns is also crucial to assess the long-term impact of new drugs and ensure equitable access to effective therapies.